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Background: Snail, a transcriptional factor and repressor of E-cadherin is well known for its role in cellular invasion.
It can regulate epithelial to mesenchymal transition (EMT) during embryonic development and in epithelial cells.
Snail also mediates tumor progression and metastases. Silencing of Snail and its associate member Slug in human
A2780 ovarian epithelial carcinoma cell line was investigated to identify its role in tumor neovascularization.
Methods: Live cell sialidase, WST-1 cell viability and immunohistochemistry assays were used to evaluate sialidase
activity, cell survival and the expression levels of tumor E-cadherin, N-cadherin, VE-cadherin, and host endothelial
CD31+(PECAM-1) cells in archived paraffin-embedded ovarian A2780, A2780 Snail shRNA GIPZ lentiviral knockdown
(KD) and A2780 Slug shRNA GIPZ lentiviral KD tumors grown in RAGxCγ double mutant mice.
Results: Oseltamivir phosphate (OP), anti-Neu1 antibodies and MMP-9 specific inhibitor blocked Neu1 activity
associated with epidermal growth factor (EGF) stimulated A2780 ovarian epithelial carcinoma cells. Silencing Snail in
A2780 cells abrogated the Neu1 activity following EGF stimulation of the cells compared to A2780 and A2780 Slug KD
cells. OP treatment of A2780 and cisplatin-resistant A2780cis cells reproducibly and dose-dependently abated the cell
viability with a LD50 of 7 and 4 μM, respectively, after 48 h of incubation. Heterotopic xenografts of A2780 and A2780
Slug KD tumors developed robust and bloody tumor vascularization in RAG2xCγ double mutant mice. OP treatment at
50 mg/kg daily intraperitoneally did not significantly impede A2780 tumor growth rate but did cause a significant
reduction of lung metastases compared with the untreated and OP 30mg/kg cohorts. Silencing Snail in A2780 tumor
cells completely abrogated tumor vascularization, tumor growth and spread to the lungs in RAGxCγ double mutant
mice. A2780 and A2780 Slug KD tumors expressed high levels of human N- and VE-cadherins, and host CD31+
endothelial cells, while A2780 Snail KD tumors expressed E-cadherin and reduced host CD31+ cells. OP 50mg/kg
cohort tumors had reduced numbers of host CD31+ cells compared to a higher expression levels of CD31+ cells in
tumors from the untreated control and OP 30mg/kg cohorts.
Conclusion: Snail transcriptional factor is an important intermediate player in human ovarian tumor neovascularization.
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Epithelial ovarian cancer is a major cause of gynecologic
cancer-associated deaths [1]. Patients with ovarian cancer
have a low 5-year survival with frequent recurrences and
rapid metastases to the peritoneal cavity with concomitant
malignant pleural effusions. The increased invasiveness
and motility of ovarian tumor cells are facilitated by sev-
eral molecular players that involve epithelial-mesenchymal
transition (EMT) [2-5]. One of the major transitions of
EMT is the loss of E-cadherin expression which is a cell–
cell adhesion molecule that participates in homotypic,
calcium-dependent interactions to form epithelial adhe-
rens junctions [6]. Loss of E cadherin expression is well
correlated with tumor grade and cancer stage. Several mo-
lecular mechanisms underlying loss of E-cadherin expres-
sion have been identified. For example, hyper-methylation
of the E-cadherin promoter and alterations in transcrip-
tion, but not mutations have emerged as one of the major
mechanisms responsible for E-cadherin down-regulation
in most carcinomas [7]. In addition, several transcriptional
repressors of E-cadherin have been identified, including
the zinc-finger factors Snail and Slug, the two-handed zinc
factors ZEB-1/dEF1 and ZEB-2/SIP1 and the basic helix-
loop-helix transcription factors Twist and E12/E47 (the
E2A gene product). Epithelial cells that ectopically ex-
press E47 adopt a fibroblastic morphology that de-
velops tumorigenic and migratory/invasive properties
with a concomitant loss of E-cadherin. The integration
of these transcriptional suppressor families in epithelial
carcinoma plasticity is eloquently reviewed by Grunert
et al. [2] and Cano and colleagues [8].
Unlike most carcinomas that dedifferentiate during
neoplastic progression with loss of epithelial E-cadherin,
ovarian carcinomas undergo a transition to a more epi-
thelial phenotype, early in tumor progression, with in-
creased E-cadherin expression. Subsequent reacquisition
of mesenchymal features is observed in late stage tumors,
and a loss of E-cadherin expression or function is an ob-
served feature in ovarian cancer progression [9-11]. In-
deed, it has been reported that epidermal growth factor
(EGF) receptor (EGFR) is frequently elevated in epithelial
ovarian cancer, and that E-cadherin expression is often re-
duced in the advanced stages of the disease [12]. Hudson
and colleagues have shown that EGFR activation promotes
a phosphatidylinositol 3-kinase (PI3K)-dependent induc-
tion of a cell surface pro-MMP-9 binding component that
facilitates gelatinase-mediated cellular invasion [13]. This
EGFR activation was shown to promote disruption of
adherens junctions through induction of MMP-9. Stable
overexpression of MMP-9 led to a loss of E-cadherin and
junctional integrity, and promoted a migratory and inva-
sive phenotype in ovarian cancer. Others have reported
additional confirmation that the expression of zinc-finger
factor Snail is associated with an increase in the promoteractivity and expression of MMP-9, and that the induced
transcription of MMP-9 by Snail is driven by a mechanism
dependent on the MAPK and PI3K signaling pathways
[14]. Collectively, these findings indicate that MMP-9
transcription is activated in response to Snail expression
and that it might explain, in part, the invasive properties
of the Snail-expressing cells. The MMP-Snail signaling
axis and its functional role in tumor progression with an
insight into new anti-cancer therapeutic strategies is elo-
quently reviewed Przybylo and Radisky [15].
Cancer cells utilize signaling initiated by EGFRs to es-
tablish an anti-apoptotic state within the cell as well as
to up-regulate mitogenic, angiogenic and pro-invasive
cellular mechanisms [16]. The activation of the EGF
receptors regulates many processes associated with me-
tastasis, including modulation of cell-cell and cell-
substrate interactions, production of matrix-degrading
proteinases, and cellular migration. EGFR signaling has
also been linked to EMT [17]. For an example, thera-
peutic strategies targeting the EGF receptors and their
inhibition caused a reversal of EMT in human pancre-
atic cancer [17]. Other studies have suggested the po-
tential role of growth factor receptor signaling in
establishing chemo-resistance in cancer cells and tu-
mors [18-22]. Signals derived from the cellular micro-
environment can also regulate EMT, such as cell–cell
contacts mediated by families of transmembrane recep-
tors and ligands expressed on adjacent cells [23]. At the
genetic level, several transcriptional suppressor families
are known that regulate EMT, including the zinc-finger
proteins Snail1 (Snail) and Snail2 (Slug), the two-
handed zinc-finger δEF1 family factors (δEF1/Zeb1 and
SIP1/Zeb2), and the basic helix–loop–helix factors,
Twist and E12/E47 [23]. What is less clear is the direct
relationship between EMT and transcriptional suppres-
sor factors in tumor neovascularization.
An insight into the mechanism of EGF-induced receptor
activation came from our recent report on Neu1 sialidase
and MMP-9 cross-talk in regulating EGF receptors [24].
The report discloses a receptor signaling paradigm involv-
ing an EGF-induced G-protein coupled receptor (GPCR)-
signaling process and MMP-9 activation to induce Neu1.
This tripartite complex of neuromedin B GPCR, MMP-9
and Neu1 forms an alliance with EGFR tethered at the
ectodomain of the receptor on the cell surface. Active
Neu1 in complex with EGFR hydrolyzes α-2,3-sialyl resi-
dues of the receptors, enabling the removal of steric hin-
drance to receptor association and allowing subsequent
dimerization, activation, and cellular signaling. A striking
similarity of this novel receptor signaling platform was re-
ported by us for nerve growth factor (NGF) TrkA recep-
tors [25], insulin receptors [26], cell surface TOLL-like
receptor-4 (TLR-4) [27-31] and intracellular TLR-7 and -9
[32]; these receptors are known to play major roles in
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to specifically target and inhibit Neu1 activity associated
with these ligand-induced receptor activations [25,31,33].
The findings in the report for EGF receptors also propose
an alternate therapeutic approach using OP as an anti-
cancer agent targeting Neu1 sialidase as the key central
enzyme within this novel EGFR signaling platform. Pre-
clinical molecular-targeting studies provide the proof-of-
evidence for an effective OP therapy in the treatment of
human pancreatic cancer growth and metastatic spread in
heterotopic xenograft of tumors growing in RAGxCγ
double mutant mice [24]. In addition, OP overcame the
chemo-resistance of pancreatic cancer PANC1 cells to cis-
platin and gemcitabine alone or in combination in a dose-
dependent manner, and disabled the cancer cell survival
mechanism(s) against the chemotherapeutic drugs [22].
More interestingly, the data in the report also provided
additional confirmation for OP therapy in reversing EMT
characteristic of E- to N-cadherin changes associated with
resistance to standard, clinical chemotherapeutics.
This present report describes another molecular level
of a novel organizational signaling platform connecting
the Snail-MMP-9 signaling axis in amplifying the Neu1
sialidase and MMP-9 cross-talk in regulating EGF recep-
tors, tumor neovascularization, growth and invasiveness.
Methods
Cell lines
A2780 (human ovarian epithelial carcinoma, Sigma-
Aldrich cat # 93112519) was established from tumor
tissue from an untreated patient. A2780 is the parent
line to the cisplatin resistant cell line A2780cis (Sigma-
Aldrich cat # 93112517). The cells were grown in a 5%
CO2 incubator at 37°C in culture containing Dulbecco’s
Modified Eagle’s Medium (Gibco, Rockville, MD, USA)
supplemented with 10% fetal calf serum (HyClone, Logan,
UT, USA) and 5 μg/mL Plasmocin™ (InvivoGen, San
Diego, CA, USA). When the cells reached ∼ 80% conflu-
ence, they were passaged at least five times for use in the
experiments.
Silencing Snail and Slug mRNA in A2780 cells using GIPZ
lentiviral shRNA transfection particles
Human Snail (gene symbol SNAIL1, V3LHS-32872 at
1.7 × 108 transducing unit (TU)/mL) and Slug (gene
symbol SNAI2, V3LHS-390965 at 3.98 × 108 TU/mL)
pGIPZ lentiviral shRNA ready-to-use particles (based
on miR-30 for gene knockdown) were obtained from
Thermo Scientific (Open Biosystems). The GIPZ Lenti-
viral shRNA platform minimizes the potential gener-
ation of recombinant viruses to the highest level by
combining a disabled viral genome with the proprietary
Trans-Lentiviral packaging process. The protocol uses a
third generation self-inactivating packaging system meetingBioSafety Level 2 requirements with the University Biohaz-
ard committee approval. The GIPZ Lentifect particles
include a CMV promoter for efficient expression of non-
tagged eGFP in target cells and use a puromycin resistance
marker for selection of stably transduced cells. Ready-to-
use lentiviral particles were used for the transduction of
A2780 ovarian carcinoma cells. Briefly, cells were cultured
in 6 well tissue culture plates in DMEM medium contain-
ing 10% FCS and 5 μg/mL plasmocin. After 24 h, medium
was discarded and 2 mL of 5 μg/mL of polybrene media
was added to the cells followed by GIPZ lentiviral shRNA
particles at MOI = 6. The plate was mixed, centrifuged at
2500 rpm for 90 min and incubated at 37°C in 5% CO2 hu-
midified incubator for 24 h. The cells were washed and re-
cultured in media for an additional 2 days. On day 5, the
media were replaced with selection media containing opti-
mal 2 μg/mL of puromycin as pre-determined in a cell via-
bility assay. Selection media was added every 40h to
expand puromycin-resistant Snail shRNA and Slug shRNA
transduced A2780 cell clones. The transfection efficiency
was determined to be 99% knockdown for both Snail and
Slug using RT-PCR analyses of total RNAs from parental
A2780, Snail shRNA and Slug shRNA knockdown cells.
Reagents
Epidermal growth factor (EGF; Sigma-Aldrich, St. Louis,
MO), the natural ligand of the EGF receptor, was reconsti-
tuted in sterile 1× phosphate buffered saline (PBS) at a
stock concentration of 1 mg/mL and stored at −20°C. EGF
concentrations to stimulate cells were 30–100 ng/mL. In-
cubation times vary between experiments and thus are
indicated.
cis-Diamineplatinum(II) dichloride (P4394, Sigma-Aldrich
Canada Ltd) was dissolved in dimethyl sulfoxide (DMSO)
to create a 27.7mM cisplatin stock. Gemcitabine hydro-
chloride (G6423, Sigma-Aldrich Canada Ltd) was dissolved
in phosphate-buffered saline (PBS) to create a 133.5 mM
gemcitabine stock. 5-Fluorouracil (5-FU) (F6627, Sigma-
Aldrich Canada Ltd) was dissolved 1 mL DMSO plus 9 mL
PBS to create a 2.31 mM 5-FU stock. Paclitaxel from Taxus
brevifolia, ≥95% (HPLC) (T7402, Sigma-Aldrich Canada
Ltd) was dissolved in DMSO to create a 1.17 mM paclitaxel
stock. These stocks were serially diluted in 1 × Dulbec-
co’s Modified Eagle’s Medium (10% fetal calf serum and
5 μg/mL Plasmocin). The stock solutions were further
diluted in the medium to make various dosages of the
chemotherapeutic agents to be used in the in vitro
experiments.
Inhibitors
Oseltamivir phosphate (OP) free base (Hoffmann-La Roche
Ltd, Mississauga, ON, Canada) was used at the concentra-
tions indicated. OP 75 mg capsules were dissolved in sterile
phosphate-buffered saline and centrifuged at 1,000 rpm for
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by us [22]. The stock-extracted oseltamivir phosphate
solution had a concentration of 15 mg/mL. Cell culture
medium containing 1 × Dulbecco’s Modified Eagle’s
Medium, 10% fetal calf serum, and 5 μg/mL Plasmocin
with different concentrations of oseltamivir phosphate
(200–800 μg/mL) were used for the in vitro and in vivo
experiments. MMP-9 inhibitor (MMP-9 Inhibitor-I,
CAS1177749-58-4, Calbiochem-EMD Chemicals Inc.)
is a cell-permeable, potent, selective, and reversible
MMP-9 inhibitor (IC50 = 5 nM). It also inhibits MMP-1
(IC50 = 1.05 μM) and MMP-13 (IC50 = 113 nM) only at
much higher concentrations.
Primary antibodies
Neutralizing antibodies were used to inhibit sialidase
function: rabbit anti-human Neu1 IgG antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Rabbit monoclonal E-cadherin antibody serum (Cell
Signaling Technology, Inc, Danvers, MA, USA), which
recognizes the human E-cadherin epitope, was used for
immunohistochemistry using a 1:400 dilution according
to the manufacturer’s instructions. Purified rabbit mono-
clonal antibody against human N-cadherin (Cell Signaling
Technology, Inc.) and human VE-cadherin (Cell Signaling
Technology, Inc.) epitopes, respectively, were used in im-
munohistochemistry at a 1:200 dilution according to the
manufacturer’s instructions.
DyLight™ 488 donkey anti-rabbit IgG secondary anti-
body (Santa Cruz Biotechnology, Inc, Santa Cruz, CA,
USA) was used at a final concentration of 40 μg/mL for
immunohistochemistry to detect primary antibodies
against human E-cadherin, N-cadherin and VE-cadherin
in paraffin-embedded xenogafts of human A2780 ovar-
ian tumors.
DyLight™ 488 rat monoclonal anti-mouse CD31
(PECAM-1) antibody (Novus Biologicals Canada ULC,
Oakville ON L6M 2V5, Canada) was used in immuno-
histochemistry at a 1:300 dilution according to the manu-
facturer’s instructions to detect mouse CD31+ (PECAM-1)
endothelial cells in the paraffin-embedded xenogafts of
A2780 ovarian tumors.
Sialidase assay in live cells
Cells were grown overnight on 12 mm circular glass
slides in conditioned medium in a sterile 24-well tissue
plate until they reached ~70% confluence as previously
optimized in the live cell sialidase assay [29,31]. After
removing medium, 0.318 mM 4-MUNANA (2′-(4-
methylumbelliferyl)-α-D-N-acetylneuraminic acid; Bio-
synth Intl.) substrate in Tris-buffered saline (TBS) pH
7.4 was added to each well alone (control), with prede-
termined dose of EGF (30 ng/mL), or in combination of
EGF and inhibitor or neutralizing antibodies at theindicated concentrations. The substrate is hydrolyzed by
sialidase to give free 4-methylumbelliferone which has a
fluorescence emission at 450 nm (blue color) following an
excitation at 365 nm. Fluorescent images were taken after
1–2 min using Zeiss M2 Imager epifluorescent micros-
copy (Carl Zeiss AG, Oberkochen, Germany) (40× object-
ive). The mean fluorescence surrounding the cells was
quantified using the Image J program.
Heterotopic xenograft mouse model of human ovarian
cancer
An immunodeficient mouse model with a double muta-
tion in the combining recombinase activating gene (RAG)
and common cytokine receptor γ chain (Cγ) was used as a
heterotopic xenograft mouse model of human ovarian
cancer as previously reported by us for human pancreatic
cancer [34]. The RAG1xCγ double mutant mice on a Nod
genetic background are completely alymphoid (T-cell, B-
cell, and NK-cell deficient), show no spontaneous tumor
formation, and exhibit normal hematopoietic parameters
[35]. Mice were generated by inter-crossing and were
maintained in SPF isolators in the Animal Care Facility,
Queen’s University, Kingston, Ontario K7L 3N6, Canada.
A colony was established in the animal facility. All mice
were kept under sterile conditions in micro-isolators or
air-filtered cages, and were provided with autoclaved food
and water. All mice used in the studies were approved by
the Animal Care Committee, Queen’s University. They
were used between 6 and 8 weeks of age.
Cancer cell implantation in RAGxCγ double mutant
xenograft mice
Parental A2780 and Snail- and Slug shRNA knockdown
A2780 cells under puromycin-resistance selection clones
were grown in 75 cm2 cell culture flask at 80% confluence.
The cells were resuspended into solution using TrypLE
Express (Gibco) and washed with sterile saline. The cell
suspension was centrifuged for 3 min at 900 rpm, and the
cell pellet suspended in sterile saline at a concentration of
5–10 × 106 cells/mL for 0.5 × 106 cell implantation cutane-
ously into the right back flank of the mouse. Tumor mea-
surements were taken twice a week. Tumor volumes were
determined by (width square/2) × length. At the endpoint
of the experiment at day 32-33 or earlier due to skin le-
sions, mice were euthanized by cervical dislocation and
live necropsy tumor, liver and lung were weighed, and par-
affin embedded for hematoxylin and eosin (H&E) staining
and immunostaining for CD31(PECAM-1) cells in tumor
tissues followed with microscopic analysis using a Zeiss
M2 Fluorescence microscope.
Immunohistochemistry
Immunohistochemistry of necropsy tumors was used to
determine the presence of the characteristic human
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N-cahderin, and the endothelial cell marker, VE-cadherin in
human A2780 tumors removed at necropsy from tumor-
bearing RAG2xCγ double mutant mice which had re-
ceived various treatments (oseltamivir phosphate 30
and 50 mg/kg, Slug shRNA KD, Snail shRNA KD or
untreated). Processed tumors were embedded in paraf-
fin blocks following necropsy in each experiment.
Tumor sections (5 μm) were deparaffinized, heated for
8 minutes in citrate buffer for antigen retrieval, placed
in 0.03% H2O2 for 30 minutes to block endogenous
peroxidases, rinsed three times in phosphate-buffered
saline, and blocked in 1% bovine serum albumin (Fisher
Scientific Company) overnight at 4°C. Deparaffinized
and processed tumor sections (5 μm) were treated with
4% bovine serum albumin in Tween-Tris buffered sa-
line and immunostained with primary and secondary
antibody over one-hour periods. The primary antibody
contained 2μg/mL rabbit anti-E-cadherin, anti-N-cadherin
or anti-VE-cadherin followed with secondary donkey anti-
rabbit IgG Alexa Fluor 488. The stained cells covered with
Entellan® rapid mounting media were observed using a
Zeiss M2 fluorescence microscope at 200× magnification.
In addition, paraffin-embedded tumors were analyzed for
mouse endothelial marker, CD31/PECAM-1. The primary
antibody at 1:300 dilution of a stock 1 mg/mL of rat
monoclonal antibody conjugated with DyLight-488 fluoro-
chrome against mouse CD31/PECAM-1 (Novus Biologi-
cals Canada ULC, Oakville, ON L6M 2V5 Canada).
WST-1 assay
The WST-1 assay, a measure of cell viability based on the
reduction of a tetrazolium compound to a soluble deriva-
tive was used [36]. The absorbance recorded at 420 nm is
directly proportional to the number of living cells in cul-
ture. At 80%–90% confluence, cells were added to 96-well
micro-well plates at a density of 5,000 cells/well and incu-
bated overnight. They were then exposed to increasing
concentrations of OP or left untreated as controls for 24,
48, and 72 hours. Absorbance readings were taken at 0, 24,
48, and 72 hours by adding WST-1 (Roche Diagnostics
Division de Hoffman La Roche Limitée, Laval-des-Rapides,
QC, Canada) as a cell proliferation reagent to each well
(10% WST-1 in Dulbecco’s Modified Eagle’s Medium)
followed by incubation at 37°C for 2 hours before reading
at the indicated time points. Cell viability was presented as
a percentage of control, and illustrated as a bar graph using
GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA). The following formula was used to determine
cell viability as a percent of control for each time point and
OP/chemotherapeutic drug concentration:
[(Absorbance of cells in given concentration of drug) –
(Media absorbance)]/[(Absorbance of cells alone) –
(Media absorbance)] × 100.Statistical analysis
Statistical analysis was carried out using GraphPad
Prism. Results were compared by a one-way ANOVA at
95% confidence using Bonferroni’s multiple comparison
test or unpaired t-test.
Results
Neu1 sialidase activity is associated with epidermal
growth factor (EGF) stimulation of A2780 ovarian
carcinoma cells
Since the co-expression of EGFR and MMP-9 has prog-
nostic value in cancer [37,38], and Neu1 and MMP-9
cross-talk regulates EGFRs in pancreatic cancer cells [34],
we investigated the molecular targeting potential of the
Neu1–MMP9 crosstalk platform in human ovarian cancer
cell lines in vitro. Here, we performed a sialidase assay on
the live cells as previously described [29,31,39]. As shown
in Figure 1A, EGF stimulation of live A2780 cells induced
sialidase activity. This sialidase activity is revealed in the
periphery surrounding the cells using a fluorogenic sialid-
ase specific substrate, 4-MUNANA [2′-(4-methylyumbel-
liferyl)-α-D-N-acetylneuraminic acid], which fluoresces at
450 nm caused by the emission of 4-methylumbelliferone.
The mean fluorescence of 50 multi-point replicates was
quantified using the Image J software and is depicted in
the bar graph. We also used specific neutralizing anti-
bodies against the human Neu1 as well as the neuraminid-
ase inhibitor oseltamivir phosphate (OP) and a specific
inhibitor of MMP9, all of which blocked the sialidase
activity associated with EGF-treated live A2780 cells com-
parable to the levels of no EGF treated controls. The anti-
Neu1 antibody used here is specific for the epitope
corresponding to amino acids 116–415 mapping at the
C-terminus of Neu1 of human origin. It also detects Neu1
of mouse, rat and human origin. The data depicted in
Figure 1A are consistent with our previous report with
EGF receptors in pancreatic cancers [34].
If Snail induces MMP-9 activation as previously re-
ported [13,14], we hypothesized that silencing Snail and
its associated member Slug with shRNA lentiviral trans-
fection of A2780 cells would indirectly block EGF-
induced Neu1 sialidase activity at the ectodomain of the
receptor. The data in Figure 1 support the hypothesis
and provide additional evidence involving a role for Snail
(Figure 1C) but not Slug (Figure 1B), indirectly regulat-
ing Neu1 sialidase activity associated with EGF-treated
live A2780 cells.
Viability of A2780, cisplatin-resistant A2780cis, A2780
shRNA Snail and A2780 shRNA Slug cells when treated
with oseltamivir phosphate (OP) at different doses using
the WST-1 assay
To test the in vitro effects of OP on the cell viability of
A2780 and cisplatin-resistant A2780cis cells, the cells
Figure 1 EGF induces sialidase activity in live (A) A2780 ovarian cancer cells, (B) A2780 shRNA Snail and (C) A2780 shRNA Slug.
Cells were allowed to adhere on 12 mm circular glass slides in media containing 10% fetal calf sera for 24 h. After removing media, 0.318 mM
4-MUNANA substrate (2′-(4-methlyumbelliferyl)-α-N-acetylneuraminic acid) in Tris buffered saline pH 7.4 was added to live cells alone (control) or
with EGF alone and in combination with OP, anti-Neu1 neutralizing antibodies, and specific inhibitor of MMP-9i at the indicated dosage. Fluorescent
images were taken at 1-2 min after adding substrate using Zeiss Imager M2 epi-fluorescence microscopy (20× objective). The mean fluorescence of 50
multi-point replicates was quantified using the Image J software. The data are a representation of one out of three independent experiments showing
similar results.
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allowed to adhere for 24 hours in 1 × Dulbecco’s Modi-
fied Eagle’s Medium containing 10% fetal calf serum.
The medium was replaced with fresh Dulbecco’s Modi-
fied Eagle’s Medium containing 5% fetal calf serum with-
out and with various concentrations of pure OP for 24
and 48 hours as predetermined. Cell viability as a per-
centage of control ± S.E. of triplicate values was deter-
mined using the WST-1 cell proliferation assay, which is
a measure of cell viability based on the reduction of aFigure 2 Cell viability of (A) A2780, (B) A2780cis cells, (C) A2780 shRN
doses using the WST-1 assay. Cells were incubated in 96 well plates (500
containing 10% FCS. The media were replaced with fresh DMEM media co
indicated time periods. Cell viability was expressed as a percent of control
three independent experiments showing similar results. LD50 value is given
for each of the cell lines.tetrazolium compound to the soluble derivative [36].
The data shown in Figure 2A and 2B indicate that treat-
ment of these ovarian cancer cell lines with OP reprodu-
cibly and dose-dependently decreased the cell viability
(as a percentage of untreated control) with an LD50 of
7μM for A2780 (Figure 2A) and 4μM for A2780cis
(Figure 2B) after 48 h of incubation. We also tested the
in vitro effects of OP therapy on cell viability using the
A2780 shRNA Snail and shRNA Slug cell clones. The
data shown in Figure 2C and 2D indicate that OPA Slug and (D) A2780 shRNA Snail treated with OP at different
0 cells/well) and allowed to adhere for 24 h in 1× DMEM media
ntaining 5% FCS without or with various concentrations of OP for
± S.E. of triplicate values. The data are a representation of one out of
as μM of drug concentration as determined by WST-1 assay after 48h
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the cell viability (as a percentage of untreated control)
with an LD50 of >488μM for both A2780 shRNA Slug cells
(Figure 2C) and A2780 shRNA Snail cells (Figure 2D)
after 48h of incubation.
It is noteworthy that the OP LD50 value of 4μM for
the cisplatin-resistant A2780cis cells was ∼ 2-fold lower
than that for the parental A2780 cell line. These data are
consistent with the results of our previous report indi-
cating that treatment of long term chemo-resistance
of PANC1 pancreatic cancer cells against 80μM cis-
platin (PANC1-CisR) with OP caused a significant dose-
dependent ∼ 96% reduction of cell viability [22]. It was
hypothesized that cisplatin-resistant A2780cis cells in
the presence of OP become more sensitive to the chemo-
therapeutic agent, resulting in decreased viability of the
A2780cis cells. Using the WST-1 assay, the cell viability of
A2780 cells treated with different dosages of OP in com-
bination with 1μM of cisplatin, 5-FU, gemcitabine and
paclitaxel was compared with that of the monotherapy of
the chemo-drugs alone. The data in Figure 3 show that for
the combination with cisplatin and 5-FU, only OP dos-
age ≥ 600μg/mL reduced cell viability at 72h compared to
monotherapy, while OP does not apparently affect the ac-
tivity of either gemcitabine or paclitaxel, when compared
to the cell viability after single chemo-drug treatment.
Targeting Neu1 with OP attenuates metastatic spread to
lungs in heterotopic xenografts of A2780 cancer cells in
RAGxCγ double mutant mice
The preclinical in vivo anti-tumor activity of OP was in-
vestigated in the RAGxCγ double mutant xenograft
mouse model of human ovarian A2780 cancer cells. The
RAGxCγ double mutant mice lack mature T cells, BFigure 3 Cell viability of A2780 cells treated with OP at indicated dos
paclitaxel using the WST-1 assay. Cells were incubated in 96 well plates
containing 10% FCS. The media were replaced with fresh DMEM media co
48 and 72 hr as predetermined optimally. Cell viability was expressed as acells, and functional NK cells, and are deficient in cyto-
kine signaling, leading to better engraftment of human
cells than any other published mouse strain [34]. As pre-
viously demonstrated for pancreatic epithelial carcinoma
cell line [34], the hypothesis is that OP therapy prevents
the in vivo growth and spread of ovarian tumors in the
heterotopic xenograft mouse model of human ovarian
cancer. A2780 ovarian carcinoma cells at 0.5 × 106 cells
in 0.2 mL were implanted cutaneously in the right back
flank of these mice. Twice a week, each mouse following
implantation of the cancer cells was monitored for
tumor volume growth at the site of implantation, body
weight, and body condition scoring. All of the experi-
mental mice did not show loss of body weight and body
condition scoring was normal until they developed skin
lesions. Scoring the body condition of rodents is a non-
invasive method for assessing health and establishing
endpoints for adults where body weight is not a viable
monitoring tool. For heterotopic implantation of A2780
cells, mice developed skin lesions due to the abnormal
tumor vascularization, which was the end-point for body
condition scoring. The data shown in Figure 4A show
(a) live tumors with skin lesions for each mouse (labelled
A1-4, B1-4 and C1-4), and (b) necropsy tumors with an
unexpected, abnormal robust and bloody tumor vascula-
ture at day 33 or earlier post implantation of A2780
cells. Due to the abnormal tumor vasculature, we also
immunostained paraffin-embedded tumors from each
mouse for host endothelial cell marker CD31/PECAM-1.
The data in Figure 4A show extensive migration of host
CD31+ cells in the tumors for the untreated and 30mg/kg
OP treated cohorts. For the 50mg/kg OP cohort, there
were markedly less host CD31+ cells in the tumor tissues.
Treatment with 30 and 50 mg/kg of soluble OP in sterilees in combination with 1 μM of cisplatin, 5-FU, gemcitabine and
(5000 cells/well) and allowed to adhere for 24 h in 1× DMEM media
ntaining 5% FCS without or with various concentrations of OP for 24,
percent of control ± S.E. of three independent experiments.
Figure 4 OP treatment of RAGxCγ double mutant mice bearing heterotopic xenograft of A2780 tumors. A2780 cells at 0.5 × 106 in 0.2 mL
were implanted cutaneously in the right back flank of these mice. Twice a week following implantation of the cancer cells each mouse was
monitored for tumor volume ((width square/2) × length) at the site of implantation. Mice were treated with 30 and 50 mg/kg of OP in sterile
saline i.p. daily at day 7 post-implantation when the tumor volume reached approximately 50 mm3. (A) Tumor growth rates for individual mice
(mouse label A1-4 for the control cohort; B1-4, 50mg/kg OP cohort and C1-4, 30mg/kg cohort). (B) Representative tumors on the right flank of the
individual animals at end-point, necropsy of live tumors, H&E staining and immunostaining for mouse CD31+ (PECAM-1) cells of tumor tissues.
Abdulkhalek et al. Clinical and Translational Medicine 2014, 3:28 Page 8 of 16
http://www.clintransmed.com/content/3/1/28saline with daily injections intraperitoneally at day 7 post-
implantation when the tumor volume reached 50 mm3
did not attenuated the aggressive tumor vascularization
with skin lesions (Figure 4A), nor the tumor growth
(Figure 4B). The treatment regimen with OP was based
on previously reported results on pancreatic cancer [34]
and unpublished results using breast epithelial triple nega-
tive carcinoma. It is proposed that OP treatment regimen
for cancers with robust tumor vascularization requires
higher doses for attenuating tumor growth as shown by
results for pancreatic cancer [34].
Live necropsy lungs (Figure 5A) showed no visible
tumor nodules. There were no tumor nodules nor meta-
static clusters of cancers cells in the liver for each of the
cohorts (data not shown). Surprisingly, the daily dosage
of 50 mg/kg OP treatment intraperitoneally significantly
attenuated the metastatic spread of ovarian cancer cells
to the lung (Figure 5B) compared to the extensive meta-
static clusters of cancer cells in the lung for the un-
treated and the 30mg/kg OP cohorts. This lack of
metastatic spread of the ovarian cancer cells to the lung
following OP treatment is highly dose dependent on thetreatment regime, which may be due to in part of a dis-
ruptive tumor vasculature development (reduced host
CD31+ endothelial cell migration) or result in a decreased
expression of the cell surface mesenchymal marker, N-
cadherin, and an increased expression of the cell surface
epithelial marker, E-cadherin as previously reported by us
for pancreatic cancer [22].
Silencing transcriptional repressor Snail disables human
ovarian carcinoma tumor neovascularization and
abolishes heterotopic xenografts of tumor growth and
metastasis in RAGxCγ double mutant mice
Although Snail is critical for ovarian cancer growth and
metastasis in animal models and human specimens
[14,40], its role in tumor neovascularization remains un-
known. Since xenografts of A2780 ovarian tumors pro-
duce abnormal robust and bloody tumor vascularization
in RAGxCγ double mutant mice (Figure 4B), we investi-
gated whether silencing Snail and its associated member
Slug in A2780 cells would attenuate tumor neovasculari-
zation in these mice. Using selection media under puro-
mycin, Snail shRNA and Slug shRNA transfected A2780
Figure 5 H&E staining of necropsy lung for number of metastatic clusters per lung in paraffin-embedded tissues taken from xenograft
A2780 tumor-bearing RAGxCγ double mutant mice. (A) Mice were implanted with 0.5×106 A2780 cells cutaneously on the rear flank and OP
treatment began daily (i.p.) 7 days post implantation when tumors reached 50 mm3. Paraffin-embedded tissue sections (5 μm) on glass slides
were processed for H&E staining fir each mouse necropsied at indicated day post-implantation. Stained tissue sections were photographed using
AxioCam MRc5 digital color camera attached to a Zeiss Imager M2 fluorescence microscope at 400× magnification. Images are representative of
at least five fields of view from two tissue sections. (B) Metastatic lung clusters as representative in the insert were microscopically counted per
tissues and plotted in the graph. Statistical analysis was carried out using GraphPad Prism and results were compared by unpaired t-test.
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knockdown as determined using RT-PCR analysis using
total RNAs from parental A2780 and Snail and Slug
shRNA knockdown cells. The data in Figure 6 clearly
demonstrate that silencing Snail but not its Slug associ-
ated family member in A2780 cells completely abrogated
not only the robust and bloody tumor vascularization
(Figure 6B), but also tumor growth (Figure 6A) and meta-
static spread to the lung (Figure 7B) in RAGxCγ double
mutant mice. There were no metastatic foci in the liver
(data not shown).
In addition, the A2780 shRNA Snail xenograft tumors
(Figure 8A) expressed higher levels of E-cadherin compared
to N- and VE-cadherins in contrast to a high expression
levels of N- and VE-cadherins in A2780 and A2780 Slug
shRNA KD xenograft tumors (Figure 8C,D and E). These
findings are consistent with other reports on the role of
Snail and E-cadherin in ovarian cancer [40-44].
Discussion
There is substantial evidence to indicate that the zinc-
finger transcriptional factors Snail and Slug, the two-
handed zinc factors ZEB-1/dEF1 and ZEB-2/SIP1 and
the basic helix-loop-helix transcription factors Twist and
E12/E47 play major roles in epithelial carcinoma plasti-
city [2,15,41,42], and in tumor progression and invasive-
ness [8,40,43,44]. Since Snail is identified as a potent
EMT mediator, others have reported that it controls the
proteolytic activity of the MMPs that contribute to thephenotypic changes associated with EMT and invasion
[40]. Their data indicated that knockdown of Snail ex-
pression reduced the mRNA level of MMP-2 and sup-
pressed the gelatinolytic activity of MMP-2 and MMP-9
in vitro, and inhibited the catalytic activity of MMP-2
in vivo. It was proposed that Snail plays an essential role
in up-regulating the proteolytic activity of MMPs during
invasion and metastasis. Others have provided additional
confirmation for Snail in inducing MMP-1, -2, -7 and -14
in liver and squamous cell carcinoma lines [45] as well as
MMP-9 in MDCK epithelial cells [14]. However, the mo-
lecular mechanism(s) by which the Snail-MMP signaling
axis functions in tumor neovascularization remained un-
known until now.
Recently, we have reported a novel organizational sig-
naling platform linked to the EGF-induced receptor acti-
vation process in live EGFR-expressing cells [34]. This
signaling paradigm proposes that EGF binding to its re-
ceptor on the cell surface induces a conformational
change of the receptor to initiate MMP-9 activation to
induce Neu1. Activated Neu1 hydrolyzes α-2,3-sialyl res-
idues linked to β-galactosides, which are distant from the
EGF binding sites. These findings predict a prerequisite
desialylation process by activated Neu1 enabling the re-
moval of steric hindrance to receptor association which is
stabilized by galectin-3. How Neu1 sialidase is rapidly in-
duced by MMP-9 remains unknown. It can be speculated
that EGF binding to EGFR on the cell surface initiates a
GPCR-signaling via GPCR Gα subunit proteins to activate
Figure 6 A2780, A2780 shRNA Snail and A2780 shRNA Slug ovarian cancer cells in heterotopic xenograft of tumors growing in
RAGxCγ double mutant mice. (A) Cells at 0.5×106 in 0.2 mL were implanted cutaneously in the right back flank of these mice. Twice a week following
implantation of the cancer cells each mouse was monitored for tumor volume ((width square/2) × length) at the site of implantation. Mice were sacrificed
at day 24 post-implantation. (B) Representative tumors on the right flank of the animal, necropsy tumors and H&E staining of tumors; N/A, not available
due to lack of tumor. (C) Paraffin-embedded tumor sections (5μm) on glass slides were processed for immunohistochemistry using primary DyLight 488
conjugated rat monoclonal anti-mouse CD31+ (PECAM-1) antibody in 1% BSA in PBS blocking solution and Entellan® rapid mounting media. Stained
tissue sections were photographed using an AxioCamMRm3-2 fluorescence camera attached to a Zeiss Imager M2 fluorescence microscope at 400×
magnification. Images are representative of at least five fields of view from two tumor sections.
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cific inhibitors of GPCR suggest that the neuromedin B
GPCR is associated with EGF-induced sialidase activity in
live 3T3-hEGFR cells [34]. Indeed, Moody et al. [46] have
also reported that the neuromedin B GPCR regulates EGF
receptor transactivation by a mechanism dependent on
Src as well as MMP activation. It is well known that
agonist-bound GPCRs have been shown to activate nu-
merous MMPs [47], including MMP-3 [48], MMPs 2 and
9 [49,50], and the members of the ADAM family of metal-
loproteinases [51,52]. We have also reported that different
GPCR agonists can directly activate Neu1 through the
intermediate MMP-9 in order to induce transactivation of
TOLL-like receptors and subsequent cellular signaling
[28]. It is noteworthy that others have found a dramatic
increase in the activity of MMP-9 in gemcitabine-resistant
pancreatic cancer cells [53], which fits well within our mo-
lecular signaling platform of Neu1-MMP-9 cross-talk in
regulating ligand-induced receptor tyrosine kinases.
If MMP-9 is playing a major role in the activation of
Neu1 sialidase in complex with EGFR as our data sug-
gest, logistically Snail in inducing MMP-9 in ovarian
A2780 cancer cells may be the molecular mechanism(s)by which the Snail-MMP signaling axis functions in
tumor neovascularization. Indeed, EGF binding to its
receptor on the cell surface of Snail shRNA A2780 cells
revealed no Neu1 activity compared to elevated sialid-
ase activity with A2780 and Slug shRNA A2780 cells
(Figure 1). OP treatment of A2780, A2780cis, Snail
shRNA A2780 and Slug shRNA A2780 cells in culture
dose-dependently diminished the cell viability with
time. We also observed that OP, anti-Neu1 antibody
and specific inhibitor MMP-9i treatment of A2780
ovarian cancer cell line blocked Neu1 activity associ-
ated with EGF-stimulation of live A2780 cells. Based on
these observations, we propose that Neu1 might be an
intermediate candidate connecting the Snail-MMP sig-
naling axis in tumor neovascularization and in promot-
ing the growth and spread of human ovarian cancer.
Clinically, treatment of epithelial ovarian carcinoma is
based on the combination of surgery and chemotherapy.
Surgical debulking of tumors followed by platinum-
based chemotherapy is the standard treatment for ad-
vanced ovarian cancer [54]. Unfortunately, the response
rates and complete responses in advanced disease are
>80% and 40-60%, respectively. After first-line treatment
Figure 7 H&E staining of necropsy lung for number of metastatic clusters per lung in paraffin-embedded tissues taken from xenograft
tumor-bearing RAGxCγ double mutant mice. (A) Mice were implanted with 0.5×106 A2780, A2780 shRNA Slug and A2780 shRNA Snail cells
cutaneously on the rear flank and OP treatment began daily (i.p.) 7 days post implantation when tumors reached 50 mm3. Paraffin-embedded
tissue sections (5μm) on glass slides were processed for H&E staining for each mouse necropsied at indicated day post-implantation. Stained
tissue sections were photographed using AxioCam MRc5 digital color camera attached to a Zeiss Imager M2 fluorescence microscope at 400×
magnification. Images are representative of at least five fields of view from two tissue sections. (B) Metastatic lung clusters as representative in
the insert were microscopically counted per tissues and plotted in the graph. Statistical analysis was carried out using GraphPad Prism and results
were compared by unpaired t-test.
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relapse with a median progression-free survival of 18
months [55]. Intraperitoneal chemotherapy possibly im-
proves progression-free and overall survivals; however,
intraperitoneal chemotherapy has not been universally
accepted for the following reasons: toxic effects, intra-
peritoneal treatment delivery issues and complications
[54]. For advanced primary peritoneal carcinoma (PPC)
and epithelial ovarian carcinoma, it has been reported
that patients receiving primary platinum-taxane chemo-
therapy do not achieve significant clinical complete re-
sponses. PPC patients were found more likely to be
platinum resistant at 6 months and had significantly re-
duced progression-free survival, and overall survival.
Indeed, the introduction of novel agents without cross-
resistance to platinum or taxanes has been shown to im-
prove the prognosis of platinum-resistant patients [56,57].
Despite improvements using carboplatin/paclitaxel based
chemotherapy, 30% of patients with ovarian cancer fail to
respond to primary therapy with 55-75% of responders re-
lapse within 1 or 2 years from the end of primary treat-
ment and die of the disease within 5 years from their
initial diagnosis [58]. Alternatively, gemcitabine has been
shown to be active as a single agent and in combination
with other drugs, including carboplatin and paclitaxel, in
the treatment of patients with recurrent ovarian cancer
[58]. Unfortunately, other reports have observed differentchemotherapeutic complications including hypersensitiv-
ity pneumonitis-like patterns in gemcitabine-induced
cases [59] and hypersensitivity reactions to oxaliplatin
[60]. Based on our present results, it is proposed that ovar-
ian carcinoma treatment regimens could follow a combin-
ation therapy of OP at a high dose with low dose of either
cisplatin, 5-FU, gemcitabine or paclitaxel. The data in
Figure 3 show that for the combination with cisplatin
and 5-FU, only OP dosage ≥ 600μg/mL reduced cell via-
bility at 72h compared to monotherapy, while OP did
not apparently affect the activity of either gemcitabine
or paclitaxel, when compared to the cell viability after
single chemo-drug treatment. Based on the fact that
hypersensitivity reactions to standard clinical chemo-
therapeutics are noted complications in cancer patients
[59][60], it is proposed from our studies that combination
therapy of OP and standard clinical chemotherapeutics
may have a beneficial effect. Indeed, we have reported that
OP significantly inhibited endotoxin lipopolysaccharide
(LPS) induced NFκB activation and the production of nitric
oxide and pro-inflammatory IL-6 and TNFα cytokines in
primary and macrophage cell lines [31]. It was also shown
that primary macrophages obtained from hypomorphic ca-
thepsin A mice with a secondary Neu1 deficiency respond
poorly to LPS-induced proinflammatory cytokines [31].
The in vivo anti-tumor activity of OP was also investi-
gated in a RAGxCγ double mutant mouse model of
Figure 8 Fluorescence immunohistochemical detection of E-cadherin, N-cadherin, and VE-cadherin expression in paraffin-embedded
tumor tissues archived from xenograft tumors of A2780, A2780 shRNA Snail and A2780 shRNA Slug cells growing in RAGxCγ double
mutant mice. Mice were implanted with 0.5 × 106 cells cutaneously on the rear flank. (A) Live necropsy tumors. (B) H&E staining of tumor
necropsy specimens. (C) Paraffin-embedded tumor sections (5 μm) on glass slides were processed for immunohistochemistry using primary
anti-E-cadherin, N-cadherin, and VEcadherin antibodies followed with polyclonal goat anti-rabbit Alexa Fluor® 488 secondary antibody and
Entellan® rapid mounting media. Background control (Bkg) sections were prepared without the primary antibodies. Stained tissue sections were
photographed using an AxioCamMRm3-2 fluorescence camera attached to a Zeiss Imager M2 fluorescence microscope at 200× magnification. Images are
representative of at least five fields of view from two tumor sections. (D) Tissue sections were visualized and photographed using an AxioCamMRm3-2
fluorescence camera attached to a Zeiss Imager M2 fluorescence microscope at 400× magnification and software enlarged. (E) Quantitative analysis was
done by assessing the density of tumor staining corrected for background in each panel using Corel Photo Paint 8.0 2 software. Each bar in the figures
represents the mean (± standard error of the mean) corrected density of tumor staining within the respective images.
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daily dosage intraperitoneally did not significantly im-
peded A2780 tumor growth in a time-to-progression
growth rate compared to the untreated cohort. It is
noteworthy because of the robust tumor neovasculariza-
tion that the efficacy of the OP treatment would require
a high dose-dependency to ablate the tumor growth. Un-
expectedly, the 50 mg/kg OP treatment did cause a signifi-
cant reduction in the number of metastatic clusters in the
lung taken from these tumor-bearing mice (Figure 5B).
Recently, we reported that OP treatment at 100mg/kg of
pancreatic tumor-bearing RAGxCγ double mutant mice
disrupted the tumor vasculature [34]. Indeed, tumor vascu-
lature requires stringently balanced vascular endothelial
growth factor (VEGF) signaling to provide sufficient pro-
ductive angiogenesis for tumor development. Unexpectedly,
the report disclosed an increase in phospho-Smad2-Ser465/
467 and phospho-VEGFR2-Tyr1175 in the pancreatic
tumor lysates from the OP treated cohort compared to the
untreated cohort [34]. Others have found that prolongedVEGF signaling in the absence of endothelial epsins-1 and -
2 produces leaky, defective tumor angiogenesis, and thus it
was proposed to contribute to the tumor growth retard-
ation [61]. The epsins are a family of ubiquitin-binding
endocytic clathrin adaptor proteins that are important in
creating membrane curvature. It was shown that epsins-1
and -2 knockout mice exhibited highly disorganized vascu-
lar structures with increased vascular permeability in tu-
mors, which was due to an increased VEGFR2 signaling, an
increased non-productive tumor angiogenesis and a re-
tarded tumor growth [61]. VEGF binding VEGFR2 pro-
motes epsin binding to ubiquitinated VEGFR2 to facilitate
endocytosis and degradation of VEGFR2. It was proposed
that epsins-1 and -2 might function as unique attenuators
of VEGF signaling [61]. It is possible that OP treatment of
ovarian tumor-bearing mice may require stringent OP dose
dependency in order to disrupt tumor vasculature, perhaps
by blocking epsins as suggested in our previous report [34].
The findings in this report also reveal an unusual ro-
bust and bloody tumor vascularization in heterotopic
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mutant mice. This immunodeficient mouse model has a
double mutation in the combining recombinase activating
gene-1 (RAG1) and common cytokine receptor γ chain
(Cγ) [35]. The RAGxCγ double mutant mice on a Nod
genetic background are completely alymphoid (T- and B-
lymphocyte, and NK-cell deficient), show no spontaneous
tumor formation, and exhibit normal hematopoietic pa-
rameters. When Snail shRNA A2780 cells were injected
cutaneously, the xenografts of tumors showed no robust
bloody tumor vascularization compared with A2780 and
A2780 shRNA Slug tumors, and the mice were completely
devoid of tumor growth and metastatic spread to the
lungs. Our observations and other reports have shown
that the knockdown of Snail expression not only sup-
pressed ovarian cancer metastasis but also inhibited pri-
mary tumor growth [40]. Our data also indicate that Snail
not only plays a dual role in controlling the growth and
metastasis of ovarian cancer, but also functions as a medi-
ator of tumor neovascularization.
Surprisingly, we found that xenografts of Slug shRNA
A2780 tumors also revealed robust bloody tumor vascu-
lature similar to the A2780 tumors with no significant
inhibition of tumor growth and metastasis to the lungs.
To explain these findings, other reports have shown that
the transcriptional repressor Slug is a highly unstable
protein [44,62], whereas the expression of Snail plays a
more dominant role. It has been reported that the part-
ner of paired (Ppa) protein, an F-box-containing a
modular component of an E3 ubiquitin ligase, binds to
the Slug protein and promotes its degradation [62]. In
other reports, Slug by itself is incapable of triggering
EMT as a stable, long-term process, but requires the ex-
pression of Snail for a stable down-regulation of E-
cadherin [44]. In contrast, another report suggested that
Slug triggers EMT independent of Snail expression [42].
To explain the dichotomy role of Slug in mediating
EMT, it was proposed that Slug has a surveillance role
in rapidly signaling the onset of adverse conditions
which may be evaded by rapid migration of cells to a
niche more favorable for growth through Snail mediated
EMT [44]. Alternatively, the high endogenous levels of
Slug expression may promote tumorigenesis through the
acquisition of resistance to apoptosis [63]. For tumor
neovascularization, silencing Slug in ovarian A2780 cells
did not prevent the robust vascularization in RAGxCγ
double mutant mice, whereas silencing Snail in A2780
cohort had a profound complete inhibitory effect. Col-
lectively, these findings with other reports suggest that
the signaling factors in the pathways that regulate the
expression of the Snail and Slug proteins during differ-
ent developmental processes are tissue- and organism-
dependent [64]. For an example, Snail has been shown
to be expressed in renal cell carcinomas (RCCs) withpositive associations with primary tumor stage and nu-
clear grade [43]. The report found that Slug expression is
negatively associated with primary tumor stage, suggesting
the down-regulation of Slug expression during malignant
progression of RCCs. Silencing Snail with small interfering
RNA (siRNA) led to the down-regulation of MMP-2 and
MMP-9, and up-regulation of E-cadherin together with
inhibition of the cell invasion through Matrigel in vitro,
whereas siRNA for Slug showed no such effects. Jin et al.
have also demonstrated that Snail-specific antisense con-
structs blocked migration and invasion of ovarian cancer
cells by restoring E-cadherin expression [40]. Other re-
ports have shown that (a) the E-cadherin repressor Snail is
associated with cancer invasion and prognosis [43] and (b)
overexpression of Snail in epithelial MDCK cells promotes
the epithelial to mesenchymal transition (EMT) towards
the invasive phenotype [14]. The expression of Snail in
epithelial MDCK cells induced an increase in the pro-
moter activity and expression of MMP-9 through the
PI3K/MAPK signaling pathway in these cells. For A2780
ovarian cancer cells, our data provide additional confirm-
ation for Snail’s role in tumor neovascularization, the
mechanism(s) of which may involve the Snail-MMP-9
signaling axis in facilitating the signaling paradigm for
the activation of growth factor tyrosine kinase receptors
through a GPCR-signaling process and MMP-9 activa-
tion to induce Neu1 as previously reported by us [33].
Conclusion
The results of this study are the first to show the ability
of transcriptional factor Snail in mediating ovarian
tumor neovascularization. Silencing transcriptional fac-
tor Snail in A2780 ovarian carcinoma cells ablated the
abnormal robust and bloody tumor vascularization in
RAGxCγ double mutant mice with a concomitant abol-
ishment of tumor growth and metastatic spread to the
lungs. For invasive tumors like ovarian cancers, Snail
and MMP-9 expressions are closely connected since they
have both been implicated in similar invasive processes
[65]. Moreover, it has been shown that Snail induces
MMP-9 secretion via multiple signaling pathways, but par-
ticularly in cooperation with oncogenic H-Ras (RasV12),
Snail leads to the transcriptional up-regulation of MMP-9
[14]. Collectively, these different signaling paradigms in-
volved with EMT in ovarian cancer suggest that growth
factor receptor glycosylation modification involving the
receptor-signaling platform of a Neu1-MMP-9 crosstalk
may in fact be the invisible link connecting the Snail-
MMP-9 signaling axis. It follows that the therapeutic effi-
cacy of oseltamivir phosphate targeting Neu1 tethered to
these receptors would be critically dose dependent. Given
the ability of OP to increase E-cadherin expression and
decrease N-cadherin and VE-cadherin expression as previ-
ously reported by us [22], ovarian cancer treated with this
Figure 9 Graphical abstract of the Snail and MMP-9 signaling axis in facilitating a neuraminidase-1 (Neu1) and matrix metalloproteinase-9
(MMP-9) cross-talk in regulating receptor tyrosine kinases (RTKs) in ovarian cancer cells to promote tumor neovascularization. Notes: For
ovarian cancers, Snail and MMP-9 expressions are closely connected in similar invasive tumor processes. Snail induces MMP-9 secretion via multiple
signaling pathways, but particularly in cooperation with oncogenic H-Ras (RasV12), Snail leads to the transcriptional up-regulation of MMP-9. This
Snail-MMP-9 signaling axis is the connecting link in promoting growth factor receptor glycosylation modification involving the subsequent
receptor-signaling platform of a Neu1-MMP-9 crosstalk tethered at the ectodomain of RTKs. Activated MMP-9 is proposed to remove the
elastin-binding protein (EBP) as part of the molecular multi-enzymatic complex that contains β-galactosidase/Neu1 and protective protein
cathepsin A (PPCA). Activated Neu1 hydrolyzes α-2,3-sialic acid residues of RTKs at the ectodomain to remove steric hindrance to receptor
association and activation. This process sets the stage for Snail’s role in tumor neovascularization. Abbreviations: GPCR, G-protein coupled
receptor; Pi3K, phosphatidylinositol 3-kinase; GTP, guanine triphosphate; EBP, elastin binding protein; PPCA, protective protein cathepsin A.
Citation: Taken in part from Research and Reports in Biochemistry 2013:3 17–30. © 2013 Abdulkhalek et al, publisher and licensee Dove
Medical Press Ltd. This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited.
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tissue and not metastasize as our data indicate. We
propose here a graphical abstract illustrating that the
Snail-MMP-9 signaling axis maintains several import-
ant cancer growth factor receptor signaling platforms
in promoting Neu1-MMP-9 crosstalk in complex with
these receptors (Figure 9). Activated Neu1 hydrolyti-
cally cleaves α-2,3-linked sialic acid(s) from the recep-
tor’s ectodomain, the desialylation process allowing for
the removal of steric hindrance and thus for proper re-
ceptor dimerization and activation of its signaling cas-
cade networks within the cancer cell. OP treatment
strategies under dose dependence is proposed to take the
form of a horizontal approach, of which, different oncogenic
signaling pathways and macrophage-mediated tumorigen-
esis are targeted with promising therapeutic intent.Abbreviations
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